<DOC>
	<DOC>NCT02715505</DOC>
	<brief_summary>This study is designed to assess the safety and exploratory efficacy of using HSC835 in patients with Inherited Metabolic Disorders (IMD) undergoing stem cell transplantation.</brief_summary>
	<brief_title>Safety and Exploratory Efficacy of HSC835 in Patients With Inherited Metabolic Disorders (IMD)</brief_title>
	<detailed_description>This phase II study is designed to assess the safety of the Novartis product HSC835 and its ability to achieve donor blood stem cell engraftment in patients with certain Inherited Metabolic Disorders who undergo stem cell transplantation. A reduced intensity conditioning will be used prior to transplantation. Patients with Hurler syndrome, MLD, Krabbe or cALD could be eligible for this study.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<criteria>Diagnosed with Hurler syndrome, Metachromatic leukodystrophy (MLD), Globoid cell leukodystrophy (Krabbe) or Cerebral adrenoleukodystropy (cALD) Adequate organ function Availability of eligible donor material Availability of a matchedrelated donor who is not a carrier of the same genetic defect Active infection at screening Prior myeloablative transplant Pregnant or nursing women and women of child bearing potential unless using highly effective contraception methods. For the pediatric population, female patients of child bearing potential who do not agree to abstinence or agree to use highly effective contraception methods Sexually active male patients unless using condoms as contraception Human Immunodeficiency virus (HIV) infection</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hurler syndrome, MLD, Krabbe, cALD, Hematopoietic Stem Cell Transplantation (HSCT)</keyword>
</DOC>